Erratum: Treatment frontiers

Kerri Smith

Nature, 2010, vol. 467, issue 7315, 622-622

Abstract: Nature 466 (suppl.), S15–S18 (26 August 2010) This Outlook article stated that Addex Pharmaceuticals has mGluR5 modulators in phase II trials for anxiety and depression. The company says that its only disclosed mGluR5 inhibitor in development, ADX48621, will soon enter phase II testing for Parkinson’s disease levodopa-induced dyskinesia and non-Parkinson’s dystonia.

Date: 2010
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature09476 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:467:y:2010:i:7315:d:10.1038_nature09476

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature09476

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().